Novavax, Inc. (NASDAQ:NVAX) could surge as high as $12



Novavax, Inc. (NASDAQ:NVAX) has a 1 Year Target Estimate of $3.5. The stock traded with the volume of 5.78 Million in the last trading session. Novavax, Inc. opened at $1.29 and closed by showing a decrease of -4.72%. The Bid price in the last session was $1.23 x 500 and the Ask price was $1.27 x 200. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).

Novavax, Inc. has the Market Capitalization of 328.2 Million. The Stock has its 52-week High of $8.95 and 52-Week Low of $1.16 and it touched its 52-week high on Dec 17, 2015 and 52-Week Low on Sep 16, 2016.

Novavax, Inc. reported its last Earnings on Nov 09 AMC where the company reported Actual EPS of $-0.24/Share whereas, the Analyst Estimated EPS was $-0.26/share. The difference between Actual EPS and Estimated EPS was $0.02/share. This represented an Earnings Surprise of 7.7%. The company will report its next earnings on Feb 27 – Mar 3 (Est.).

6 number of analysts also provided their insight on Novavax, Inc., where the Average Price Target for the stock is $3.5. They also projected Low Price Target as $1.5 while High Price Target is set at $12.

A number of analysts rated the stock as well: 1 analysts believe that the stock is a STRONG BUY while 1 reported it as Buy.6 analysts assigned a HOLD rating, 0 said it’s UNDERPERFORM and 0 say that this stock is a SELL.

Novavax, Inc. annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 0 and Forward Price to Earnings ratio of 0. The company has its Price to Sales (P/S) ratio of 20.77 where Price to Book (P/B) ratio of 6.72, Price to Cash Per share (P/C) of 1.09 and Price to Free Cash Flow (P/FCF) has a value of 0.

The company has its Return on Assets (ROA) of -61.5 Percent. Return on Equity (ROE) stands at -189.1% and Return on Investment (ROI) displays a value of -53.6%.

The stock is currently trading at Distance from 20-Day simple moving Average of -10.96% whereas, Distance from 50-Day Simple moving average is -25.48 Percent and Distance from 200-Day Simple Moving Average of -75.71 percent.

A look at performance overview of Novavax, Inc. depicts that Performance (Week) is -3.97 percent while Performance Month is -20.39%. Quarterly performance shows a value of -82.31% and Half Year Performance value stands at -80.79%. Yearly performance of the stock has the value of -85.85 percent. Novavax, Inc. has its YTD performance of -85.58 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).

Insider Trades:

Many Insiders have done trades inside the company. The latest trade was made on 21 Sep 2016 where Officer Trizzino (John J) did a transaction type “Buy” in which 46000 shares were traded at a price of $2.17. Another insider trade includes Officer Glenn (Gregory M) who also initiated a transaction in which 1000 shares were traded on 20 Sep 2016 as “Buy”. On 20 Sep 2016 Director McManus (Michael A Jr) traded 30000 shares as “Buy” at $1.61. Director Boudreaux (Gail Koziara) Buy 100000 shares on 19 Sep 2016 at the price of $1.45.

Upgrades/Downgrades Report:

The latest Upgrades/Downgrades was done by Research firm Citigroup on 16-Sep-16 who Downgrade the stock from Buy to Neutral. Other firms have also Upgraded/Downgraded the stock. On 16-Sep-16, Wedbush took an action “Downgrade” from Outperform to Neutral. On 16-Sep-16, the stock was Downgrade to Neutral by Ladenburg Thalmann.